Press Releases
Senators Banks and Gallego Introduce the Freedom of Association in Higher Education Act
WASHINGTON, D.C. – Today, Senators Jim Banks (R-Ind.) and Ruben Gallego (D-Ariz.) introduced the Freedom of Association in Higher Education Act, a bipartisan bill that protects college students’ rights to join single-sex social organizations, like fraternities, sororities, or off-campus clubs, without fear of punishment or discrimination from their schools. Senator Jim Banks (R-Ind.): “Students should be free to form and join single-sex organizations like fraternities and sororities without facing punishment. This bill protects students’ freedom to associate, uphold tradition, and choose the communities they want to be a part of.” Senator Ruben Gallego (D-Ariz.): “I cannot imagine my college experience without my fraternity brothers.
Senator Jim Banks to Attorney General Bondi: “I urge you to investigate Code Pink for potential violations of FARA”
WASHINGTON, D.C. – Yesterday, Senator Jim Banks (R-Ind.) sent a letter to Attorney General Pam Bondi raising concerns about Code Pink’s potential violations of the Foreign Agents Registration Act (FARA) and its growing ties to the Chinese Communist Party (CCP). In part, the letter reads: “While once an American anti-war group, Code Pink has clearly become an agent of CCP influence in the United States. Despite activities and funding so blatant that even the New York Times acknowledged the organization’s activities ‘usually require’ groups to register under FARA, Code Pink has not registered with the DOJ. This failure to register represents a potential violation
Senator Jim Banks Sends Letter to Acting FDA Commissioner Regarding Dangerous Counterfeit Weight Loss Drugs
WASHINGTON, D.C. – Yesterday, Senator Jim Banks (R-Ind.) sent a letter to Dr. Sara Brenner, Acting Commissioner of Food and Drugs, regarding unregulated and potentially dangerous active pharmaceutical ingredients (APIs) being shipped to the US from foreign countries and used in injectable weight loss drugs. In part, the letter reads: “I request detailed information about how the Food and Drug Administration (FDA) will prevent unlawful APIs from entering the country and potentially harming Americans. As of December 31, 2024, the FDA’s Adverse Event Reporting System database lists more than 900 cases of adverse health events associated with compounded “semaglutide” and “tirzepatide,” of which 17